| http://www.w3.org/ns/prov#value | - FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network?? (NCCN??) Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) c
|
